KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Shares Outstanding (Diluted Average) (2017 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Shares Outstanding (Diluted Average) for 13 consecutive years, with $56.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 0.88% to $56.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $56.5 million, a 0.88% increase, with the full-year FY2025 number at $56.5 million, up 0.88% from a year prior.
  • Shares Outstanding (Diluted Average) was $56.5 million for Q4 2025 at Supernus Pharmaceuticals, up from $56.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $62.5 million in Q1 2023 to a low of $54.2 million in Q1 2021.
  • A 5-year average of $56.8 million and a median of $55.8 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 13.47% in 2022, then fell 10.93% in 2024.
  • Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $54.4 million in 2021, then grew by 13.47% to $61.7 million in 2022, then decreased by 10.01% to $55.5 million in 2023, then rose by 0.81% to $56.0 million in 2024, then rose by 0.88% to $56.5 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Shares Outstanding (Diluted Average) are $56.5 million (Q4 2025), $56.1 million (Q3 2025), and $56.6 million (Q2 2025).